医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Pacific Life Re Opens New Branch and Ready to Write Onshore Reinsurance Business in Korea

2016年03月31日 AM11:05
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

Pacific Life Re Limited, Korea Branch (“Pacific Life Re Korea”) has received regulatory approval from the Financial Services Commission (FSC) to commence writing onshore reinsurance business in Korea.

Pacific Life Re Korea is part of Pacific Life Re, the reinsurance division of the Pacific Life group. Pacific Life Re has existing offices in Asia, Europe, Australia, and North America. The ultimate parent is Pacific Mutual Holding Company, a US-based mutual life insurance company founded in 1868 with over US$137bn in Company Assets, as of December 31, 2015.

“This move demonstrates our on-going commitment to further deepen our footprint in Asia,” says Alex King, Managing Director of Pacific Life Re Asia. “We have been working with our clients in Korea since 2009, operating out of our regional hub in Singapore. The recent market reforms present us with a unique opportunity to providing a fresh and innovative approach to life reinsurance in the Korean market.”

Pacific Life Re Division CEO Dave Howell also commented, “This licence represents a further expansion of the Pacific Life Re global brand and its proposition in Asia. With a local team in place, we are enhancing our service proposition to meet the needs of the Korean insurers in the coming years.”

Pacific Life Re has a financial strength credit rating from S&P and Fitch of A+ (stable outlook).

About Pacific Life Re

Pacific Life Re works with clients in the UK, Ireland, Asia, Australia, and North America to manage their mortality, longevity, and morbidity risk. Pacific Life Re Limited is a wholly-owned subsidiary of Pacific LifeCorp, and is regulated by the Prudential Regulation Authority and the Financial Conduct Authority.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160330005480/en/

CONTACT

Pacific Life Re Limited
Simon Jun Chong, +82-2-6226-7510
Head
of Korea
simon.chong@pacificlifere.com

同じカテゴリーの記事 

  • BostonGene and Saga University Announce Collaboration to Uncover Biomarkers for Improved Immunotherapy Response in Lung Cancer Patients
  • MRMヘルス、回腸嚢炎治療薬MH002の第2a相臨床試験で安全性と良好な有効性データを報告
  • KBIバイオファーマ、Jean-Baptiste Agnus氏を最高業務責任者(CBO)に指名
  • 佐賀大学とBostonGeneがEGFR陽性肺癌患者におけるICIの治療効果予測因子を特定するための新規バイオマーカー探索を目的とした研究を発表
  • KBI Biopharma任命Jean-Baptiste Agnus为首席商务官